Every one of those 1 sits in a single category, regulation. Of the tracked stories, 1 of 1 also mention 21 CFR Part 111, the most common co-covered peer. The tracked stories average 2 original sources each. Zeon Lifesciences appears in 1 tracked Healthcare story from August 23, 2026.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Zeon Lifesciences
Every one of those 1 sits in a single category, regulation. Of the tracked stories, 1 of 1 also mention 21 CFR Part 111, the most common co-covered peer. The tracked stories average 2 original sources each. Zeon Lifesciences appears in 1 tracked Healthcare story from August 23, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 8 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Zeon Lifesciences. Shared-story counts are live from our verified record — not editorial picks.
Zeon Lifesciences' US FDA FSMA clearance and NSF 21 CFR Part 111 cGMP certification lower compliance risk for US healthcare distributors, pharmacies, and wellness brands sourcing contract-manufactured nutraceuticals from India. For procurement and quality teams, the dual credentials address critical supplier qualification requirements in the US supplement market. The milestone signals a more resilient, audit-ready international supply chain.
Zeon Lifesciences is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source
link? Report a data issue.
